Hefei Lifeon Pharmaceutical Co Ltd Total Assets
Hefei Lifeon Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Hefei Lifeon Pharmaceutical Co Ltd (003020) holds total assets worth CN¥2.61 Billion CNY (≈ $382.60 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Hefei Lifeon Pharmaceutical Co Ltd (003020) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Hefei Lifeon Pharmaceutical Co Ltd (2012–2025)
Total assets of Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2025. This chart illustrates how Hefei Lifeon Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See latest Hefei Lifeon Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Hefei Lifeon Pharmaceutical Co Ltd - Asset Composition Analysis
Hefei Lifeon Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Hefei Lifeon Pharmaceutical Co Ltd total assets breakdown as of December 2025. Hefei Lifeon Pharmaceutical Co Ltd's total assets of CN¥2.61 Billion consist of 45.5% current assets and 54.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.0% |
| Accounts Receivable | CN¥452.44 Million | 17.5% |
| Inventory | CN¥204.50 Million | 7.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥100.06 Million | 3.9% |
| Goodwill | CN¥74.44 Million | 2.9% |
Asset Composition Trend (2012–2025)
This chart illustrates how Hefei Lifeon Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 003020 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hefei Lifeon Pharmaceutical Co Ltd's current assets represent 45.5% of total assets in 2025, a decrease from 71.4% in 2012.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2025, up from 13.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 2.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 17.5% of total assets.
Hefei Lifeon Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hefei Lifeon Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Hefei Lifeon Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.44 | 2.14 | 2.89 |
| Quick Ratio | 1.95 | 1.65 | 2.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥730.06 Million | CN¥607.06 Million | CN¥885.66 Million |
Hefei Lifeon Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hefei Lifeon Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.10 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | CN¥2.59 Billion |
| Market Capitalization | $493.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hefei Lifeon Pharmaceutical Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hefei Lifeon Pharmaceutical Co Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hefei Lifeon Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total assets of Hefei Lifeon Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.59 Billion ≈ $378.39 Million |
-0.01% |
| 2024-12-31 | CN¥2.59 Billion ≈ $378.41 Million |
+4.12% |
| 2023-12-31 | CN¥2.48 Billion ≈ $363.44 Million |
+17.06% |
| 2022-12-31 | CN¥2.12 Billion ≈ $310.48 Million |
+26.71% |
| 2021-12-31 | CN¥1.67 Billion ≈ $245.02 Million |
+9.01% |
| 2020-12-31 | CN¥1.54 Billion ≈ $224.77 Million |
+72.62% |
| 2019-12-31 | CN¥889.81 Million ≈ $130.21 Million |
+15.41% |
| 2018-12-31 | CN¥771.01 Million ≈ $112.82 Million |
+25.81% |
| 2017-12-31 | CN¥612.85 Million ≈ $89.68 Million |
+11.87% |
| 2016-12-31 | CN¥547.80 Million ≈ $80.16 Million |
+15.17% |
| 2014-12-31 | CN¥475.64 Million ≈ $69.60 Million |
+6.59% |
| 2013-12-31 | CN¥446.22 Million ≈ $65.30 Million |
+24.42% |
| 2012-12-31 | CN¥358.64 Million ≈ $52.48 Million |
-- |
About Hefei Lifeon Pharmaceutical Co Ltd
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethy… Read more